SOURCE: SpectraScience, Inc.

April 06, 2015 09:15 ET

Chester Sievert Steps Down From SpectraScience's Board of Directors

SAN DIEGO, CA--(Marketwired - Apr 6, 2015) - SpectraScience, Inc. (OTCQB: SCIE), an international medical device company utilizing light technologies to detect and diagnose cancers, announced today that Mr. Chester Sievert stepped down from SpectraScience's Board of Directors effective April 2, 2015.

Mr. Sievert said, "I will always treasure and be most grateful for the privilege of being a part of SpectraScience. It is very difficult to leave something you have been so passionate about. Now that the management team has the technology platform poised for commercial success, it is a good time for me to transition off the board to pursue other interests. I remain excited and solidly assured of the Company's bright and successful future."

"I want to personally thank Chet for his dedication and significant contributions to SpectraScience. Until 2003 he served as President, CEO and Chairman of the Board. Under his direction, our optical biopsy technology was first developed, clinically studied and approved by the FDA. He has served as a board member since 2004. Speaking for all of us here at SpectraScience, we want to thank him for his contributions. He has been an important part of our company for more than a decade. We wish him all the best in his future endeavors. He will deeply missed," stated Michael Oliver, President and Chief Executive Officer.

About SpectraScience, Inc.:

SpectraScience is a San Diego-based, international medical device company. It is the only company providing true optical biopsies for cancer screening diagnosis, quantifying biomarker concentrations and physical cellular change. These light-based technologies will revolutionize the diagnosis of epithelial cancers, among the most prevalent and deadly of all cancers. The non-invasive diagnostic process is virtually instantaneous and is safer for the patient, faster for the clinician, and less expensive for the payer, resulting in improved patient care at a significantly reduced cost. With FDA approval for sale in the U.S. and the CE mark for the European Union, the WavSTAT System is the first commercially available product that incorporates these innovative technologies for clinical use.

For more information:

Visit our web site www.spectrascience.com  

Forward-Looking Statement for SpectraScience, Inc.

This news release contains forward-looking statements that involve risks and uncertainties that may cause SpectraScience's actual results to differ materially from results discussed in forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, its most recent Form 10-K and in SpectraScience's other reports filed with the Securities and Exchange Commission ("SEC") that attempt to advise interested parties of the risks and factors that may affect SpectraScience's business. These forward-looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-K and other documents.

Contact Information

  • Contacts:
    Media and Investors:
    SpectraScience, Inc.
    Lowell Giffhorn
    CFO
    Phone: (858) 847-0200 x2019
    Email: Email Contact